Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Viking Therapeutics gains amid report of renewed takeover interest (SeekingAlpha) +++ VIKING THERAPEUTICS Aktie -4,47%

VIKING THERAPEUTICS Aktie

 >Aktienkurs 
25.65 EUR    +2.8%    (TradegateBSX)
Ask: 26.35 EUR / 600 Stück
Bid: 26.25 EUR / 600 Stück
Tagesumsatz: 2709 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: +7,3%
1 Monat: -1,8%
3 Monate: -15,6%
6 Monate: -6,6%
1 Jahr: -29,7%
laufendes Jahr: -20,0%
>VIKING THERAPEUTICS Aktie
Name:  VIKING THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US92686J1060 / A12GD6
Symbol/ Ticker:  1VT (Frankfurt) / VKTX (NASDAQ)
Kürzel:  FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX
Index:  -
Profil:  Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being s..
>Volltext..
Marktkapitalisierung:  3294.74 Mio. EUR
Unternehmenswert:  2668.48 Mio. EUR
Umsatz:  -
EBITDA:  -584.23 Mio. EUR
Nettogewinn:  -565.41 Mio. EUR
Gewinn je Aktie:  -4.87 EUR
Schulden:  229.6 Mio. EUR
Liquide Mittel:  610.85 Mio. EUR
Operativer Cashflow:  -417.06 Mio. EUR
Bargeldquote:  7.17
Umsatzwachstum:  -
Gewinnwachstum:  -173.67%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  VIKING THERAPEUTICS, VIKING THERAPEUTIC
Letzte Datenerhebung:  13.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 127.52 Mio. St.
Frei handelbar: 97.07%
Rückkaufquote: -8.23%
Mitarbeiter: 53
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 231.85%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 6.31
PEG-Ratio: -0.03
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -73.07%
Eigenkaprendite: -96.37%
>Peer Group
Gesundheit, Lebererkrankungen & -behandlung/ Hepatitis, Endokrine Erkrankungen (Hormonstörungen), Stoffwechselerkrankungen (Diabetes/ Adipositas)
 
13.11.26 - 19:18
Viking Therapeutics gains amid report of renewed takeover interest (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.26 - 10:24
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028 (Fool)
 
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price....
09.11.26 - 13:09
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026 (PR Newswire)
 
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc.......
03.11.26 - 22:33
Viking Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
 
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026......
02.11.26 - 13:36
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here′s the Bull Case. (Fool)
 
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech....
30.10.26 - 18:45
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach? (Zacks)
 
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline....
30.10.26 - 15:45
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
 
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?...
29.10.26 - 19:30
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses (Zacks)
 
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies....
29.10.26 - 15:06
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases (24/7 Wall St.)
 
Eli Lilly (NYSE:LLY) just extended its lead in obesity drugs, and its newer cancer, immunology and neuroscience products are starting to matter, while the rest of the glucagon-like peptide-1 (GLP-1) group is barely moving. Eli Lilly stock is trading at $1,393, up 8%. Taking a look at the peers, Novo Nordisk (NYSE:NVO) stock is at […]...
28.10.26 - 22:18
Viking Therapeutics falls on third quarter loss miss (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
28.10.26 - 21:27
Viking Therapeutics GAAP EPS of -$1.55 misses by $0.50 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.10.26 - 21:09
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
 
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part 2 Study Initiated -- -- Phase 1 SAD Study of Amylin Agonist VK3019......
26.10.26 - 16:30
Should You Buy Viking Therapeutics Stock Ahead of Q3 Results? (Zacks)
 
VKTX is likely to report Q3 results Oct. 28 as investors await updates on VK2735's oral and injectable obesity programs and 2027 data readouts....
25.10.26 - 16:42
Why Viking Therapeutics’ Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28 (24/7 Wall St.)
 
Viking Therapeutics (NASDAQ:VKTX) reports third-quarter results on October 28, 2026. Shares fell 41.42% over the past month, so management has to make the case for its newly launched oral VK2735 Phase 3 program on this call. A Crowded Quarter Ended With a Steep Selloff Last quarter, Viking lost $1.10 per share against a -$1.21 consensus. […]...
24.10.26 - 01:00
Here′s Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market (Zacks)
 
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $24.42, signifying a -5.48% move from its prior day's close....
22.10.26 - 19:45
NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? (Zacks)
 
Viking Therapeutics' late-stage obesity drug and promising weight-maintenance data could offer greater upside than Novo Nordisk, despite higher clinical and commercial risks....
21.10.26 - 22:06
Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 (PR Newswire)
 
Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine......
20.10.26 - 16:12
Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years (Fool)
 
Viking Therapeutics has a lot riding on its leading pipeline candidate....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Um in der Gesellschaft etwas zu gelten, setzt man alles daran, so zu tun, als gelte man dort schon etwas. - François VI. Duc de La Rochefoucauld
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!